References

diaendo

Сахарный диабет

Diabetes mellitus

2072-03512072-0378

Endocrinology research centre

10.14341/2072-0351-5533

diaendo-5533

Research Article

Статьи

Articles

Ангиогенез и васкулогенез при сахарном диабете: новые концепции патогенеза и лечения сосудистых осложнений

Vasculogenesis and angiogenesis in diabetes mellitus: novel pathogenetic concepts for treatment of vascular complications

Коненков

Владимир Иосифович

Konenkov

Vladimir Iosifovich

klimontov@mail.ru

Климонтов

Вадим Валерьевич

Klimontov

Vadim Valer'evich

klimontov@mail.ru

ФГБУ "Научно-исследовательский институт клинической и экспериментальной лимфологии" СО РАМНРоссияResearch Institute of Clinical and Experimental LymphologyRussian Federation

2012

15122012

154

№4 (2012)

1727

2012

Коненков В.И., Климонтов В.В.

Konenkov V.I., Klimontov V.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.dia-endojournals.ru/jour/article/view/5533

Гипергликемия и другие нарушения метаболизма способны нарушать баланс между проангиогенными и антиангиоген- ными регуляторами и вести к неадекватному образованию новых сосудов при сахарном диабете (СД). В свою очередь, нарушения ангиогенеза и васкулогенеза являются важными механизмами в развитии сосудистых осложнений СД. Активация ангиогенеза в сетчатке рассматривается как краеугольный камень пролиферативной диабетической ретинопатии. Избыточный ангиогенез в почках наблюдается на начальных стадиях диабетического поражения почек. Напротив, развитие макрососудистых осложнений сопровождается подавлением интенсивности ангиогенеза и васкулогенеза. В последние годы были предложены новые подходы к лечению, основанные на коррекции ангиогенеза. В клинических исследованиях показана эффективность ингибиторов ангиогенеза (?анти-VEGF терапии?) при диабетическом отеке макулы и пролиферативной ретинопатии. Экспериментальные данные указывают на то, что ингибиторы ангиогенеза могут тормозить развитие диабетического поражения почек. Стимуляция ангиогенеза и васкулогенеза с помощью стволовых клеток и ростовых факторов - перспективное направление лечения поражений крупных сосудов при СД.

Hyperglycemia along with other metabolic disorders may disrupt the balance of pro- and antiangiogenic regulators, thus leading to a maladaptive formation of new blood vessels in the state of diabetes mellitus (DM). In their turn, aberrant angiogenesis and vasculogenesis are important mechanisms of vascular complications in DM. Activation of retinal angiogenesis is a cornerstone of proliferative diabetic retinopathy, though in diabetic nephropathy excessive angiogenesis is only seen at early stages. Quite on the contrary, macrovascular complications are characterized by certain inhibition of both angiogenesis and vasculogenesis. Novel therapeutic approaches, based on correction of angiogenesis, have emerged recently. Clinical trials have shown efficacy of angiogenesis inhibitors (the ?anti-VEGF? agents) for management of diabetic macular edema and proliferative retinopathy. Experimental evidence also indicates that this treatment may hinder the progress of diabetic nephropathy. In addition, stimulation of angiogenesis and vasculogenesis with stem cells or growth factors promise an option for treatment of large vessels in DM.

ангиогенездиабетические микроангиопатиимакроангиопатииингибиторы ангиогенеза

angiogenesisdiabetic microangiopathymacroangiopathyangiogenesis inhibitors

References1

IDF Diabetes Atlas. Fifth edition. International Diabetes Federation, 2011.

Konenkov VI, Borodin YuI, Lyubarskiy MS. Limfologiya. Novosibirsk: Izdatel'skiy dom «Manuskript»; 2012. Pp. 205-215, 238-265. [Russian]

Poveshchenko AF, Konenkov VI. Mechanisms and Factors of Angiogenesis. Uspekhi fiziol. Nauk. 2010; 41(2):68-89. [Russian]

Parfenova EV, Tkachuk VA. Terapevticheskiy angiogenez: dostizheniya, problemy, perspektivy. Kardiologicheskiy vestnik. 2007 (2):5-15. [Russian]

Schatteman GC, Dunnwald M, Jiao C. Biology of bone marrow-derived endothelial cell precursors. Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H1-18. Epub 2006 Sep 15.

Goligorsky MS, Kuo MC, Patschan D, Verhaar MC. Review article: endothelial progenitor cells in renal disease. Nephrology (Carlton). 2009 Apr;14(3):291-297.

Li Calzi S, Neu MB, Shaw LC, Grant MB. Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: treatment concept to correct diabetes-associated deficits. EPMA J. 2010 Mar 1;1(1):88-100.

Glaser BM, D'Amore PA, Michels RG, Brunson SK, Fenselau AH, Rice T, Patz A. The demonstration of angiogenic activity from ocular tissues. Preliminary report. Ophthalmology. 1980 May;87(5):440-446.

Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 1994; 145 (3): 574-584.

Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995 Jun;72(6):638-645.

Noma H, Funatsu H, Yamashita H, Kitano S, Mishima HK, Hori S. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch Ophthalmol. 2002 Aug;120(8):1075-1080.

Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, Gehlbach P, Melia M, Pieramici D, Harlan JB, Campochiaro PA, Zack DJ. Vitreous levels of pigment epithelium- derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol. 2004 Apr;137(4):668-674.

Brooks HL Jr, Caballero S Jr, Newell CK, Steinmetz RL, Watson D, Segal MS, Harrison JK, Scott EW, Grant MB. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004 Dec;122(12):1801-1807.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005 Aug 25;353(8):782-792.

Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2005 Mar;139(3):476-481.

Kuzmin AG, Lipatov DV, Chistyakova TA, Smirnova OM, Arbuzova MI, Ilyin AV, Shestakova MV. Vascular endothelial growth factor in the fluid of the anterior chamber of the eye in patients with diabetic retinopathy, cataract and neovascular glaucoma. Diabetes mellitus. 2010;(3):32-36. [Russian]

Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, Schlingemann RO. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci. 2002 Mar;43(3):849-857.

Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. neovascularization. Am. J. Pathol. 2000; 156 (2): 697-707.

Willard AL, Herman IM. Vascular complications and diabetes: current therapies and future challenges. J Ophthalmol. 2012;2012:209538. Epub 2012 Jan 9.

Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL, Mames RN, Segal MS, Grant MB, Scott EW. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005 Jan;115(1):86-93.

Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3784-3791. Print 2011 May.

Feng Y, vom Hagen F, Pfister F, Djokic S, Hoffmann S, Back W, Wagner P, Lin J, Deutsch U, Hammes HP. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost. 2007 Jan;97(1):99-108.

Hernández C, Simó R. Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy. Endocrine 2012; 41 (2): 220-226.

Takagi H, Watanabe D, Suzuma K, Kurimoto M, Suzuma I, Ohashi H, Ojima T, Murakami T. Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S62-64. Epub 2007 May 3.

Kase S, Saito W, Ohgami K, Yoshida K, Furudate N, Saito A, Yokoi M, Kase M, Ohno S. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br. J. Ophthalmol. 2007; 91 (10): 1376-1378.

McVicar C.M., Colhoun L.M., Abrahams J.L, Kitson CL, Hamilton R, Medina RJ, Durga D, Gardiner TA, Rudd PM, Stitt AW. Differential modulation of angiogenesis by erythropoiesis- stimulating agents in a mouse model of ischaemic retinopathy. PLoS One. 2010 Jul 29;5(7):e11870.

Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002 Sep;134(3):348-353.

Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N. Low content of the natural ocular anti-angiogenic agent pigment epitheliumderived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia. 2003 Mar;46(3):394-400. Epub 2003 Mar 1.

Abu El-Asrar AM, Nawaz MI, Kangave D, Siddiquei MM, Ola MS, Opdenakker G. Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy. Acta Diabetol. 2011 Sep 25.

Abu El-Asrar AM, Struyf S, Verbeke H, Van Damme J, Geboes K. Circulating bone-marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes. Acta Ophthalmol. 2011 May;89(3):222-228. doi: 10.1111/j.1755-3768.2009.01700.x.

Brunner S, Schernthaner GH, Satler M, Elhenicky M, Hoellerl F, Schmid-Kubista KE, Zeiler F, Binder S, Schernthaner G. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):392-398. Epub 2008 Aug 21.

Lee IG, Chae SL, Kim JC. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye (Lond). 2006 May;20(5):546-552.

Asnaghi V, Lattanzio R, Mazzolari G, Pastore MR, Ramoni A, Maestroni A, Ruggieri D, Luzi L, Brancato R, Zerbini G. Increased clonogenic potential of circulating endothelial progenitor cells in patients with type 1 diabetes and proliferative retinopathy. Diabetologia. 2006 May;49(5):1109-1111. Epub 2006 Mar 7.

Tan K, Lessieur E, Cutler A, Nerone P, Vasanji A, Asosingh K, Erzurum S, Anand-Apte B. Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopathy. Exp Eye Res. 2010 Aug;91(2):229-237. Epub 2010 May 21.

Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL, Kern TS, Grant MB. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes. 2007 Apr;56(4):960- 967.

Osterby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1987 Oct-Dec;1(4):122-127.

Min W, Yamanaka N. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Arch A Pathol Anat Histopathol. 1993;423(3):201-207.

Stout LC, Whorton EB. Pathogenesis of extra efferent vessel development in diabetic glomeruli. Hum Pathol. 2007 Aug;38(8):1167-1177. Epub 2007 May 8.

Osterby R, Asplund J, Bangstad HJ, Nyberg G, Rudberg S, Viberti GC, Walker JD. Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant. 1999 Feb;14(2):348-352.

Osterby R, Tapia J, Nyberg G, Tencer J, Willner J, Rippe B, Torffvit O. Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS. 2001 Nov;109(11):751-761.

Guo M, Ricardo SD, Deane JA, Shi M, Cullen-McEwen L, Bertram JF. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat. 2005 Dec;207(6):813-821.

Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006 May;69(9):1654-1661.

Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes. 2009 Jul;58(7):1471-1478.

Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, Watanabe T. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 2005 Feb;45(2):288-294.

Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia. 2011 May;54(5):1227-1241. Epub 2011 Feb 12.

Chiarelli F, Spagnoli A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G, Verrotti A. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type-1 diabetes mellitus: relation to glicaemic control and microvascular complications. Diabet Med. 2000 Sep;17(9):650-656.

Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, Baik SH, Choi DS, Kang YS, Han SY, Han KH, Ji YH, Cha DR. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet Med. 2004 Jun;21(6):545-551.

Бондарь ИА, Климонтов ВВ. Renal excretion of insulinlike growth factor 1 and vascular endothelial growth factor in patients with type 1 diabetes with nephropathy. Probl. endokrinol. 2007; 53(6):3-7. [Russian]

Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999 Nov;48(11):2229-2239.

Kim HW, Lim JH, Kim MY, Chung S, Shin SJ, Chung HW, Choi BS, Kim YS, Chang YS, Park CW. Long-term blockade of vascular endothelial growth factor receptor-2 aggravates the diabetic renal dysfunction associated with inactivation of the Akt/eNOS-NO axis. Nephrol Dial Transplant. 2011 Apr;26(4):1173-1188. Epub 2010 Oct 8.

Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, Takazawa Y, Sugiyama H, Yamasaki Y, Agata N, Makino H. 2-(8-hydroxy-6-methoxy-1-oxo-1h- 2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-1242.

Dessapt C, Karalliedde J, Hernandez-Fuentes M, Martin PP, Maltese G, Dattani N, Atkar R, Viberti G, Gnudi L. et al. Сirculating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care. 2010 Apr;33(4):875-877. Epub 2010 Jan 12.

Reinhard H, Jacobsen PK, Lajer M, Tarnow L, Astrup AS, Kim WY, Pedersen N, Billestrup N, Mandrup-Poulsen T, Parving HH, Rossing P. Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy. Nephron Clin Pract. 2011;118(3):c309-314. Epub 2011 Jan 21.

Krenning G, Dankers PY, Drouven JW, Waanders F, Franssen CF, van Luyn MJ, Harmsen MC, Popa ER. Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1314-1322. Epub 2009 Apr 1.

Jie KE, Zaikova MA, Bergevoet MW, Westerweel PE, Rastmanesh M, Blankestijn PJ, Boer WH, Braam B, Verhaar MC. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrol Dial Transplant. 2010 Jun;25(6):1875-1882. Epub 2010 Jan 18.

Mohler ER 3rd, Lifeng Zhang, Medenilla E, Rogers W, French B, Bantly A, Moore JS, Yonghong Huan, Murashima M, Berns JS. Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease. Vasc Med. 2011 Jun;16(3):183-189.

Parfenova ЕV, Tkachuk VА. Hyperglycemia impact on angiogenic properties of endothelial and progenitor vascular cells. Annals Of The Russian Academy Of Medical Sciences. 2012;(1):38-44.

Akopyan ZhA, Sharonov GV, Kochegura TN, Il'yashenko NF, Belyanko IE, Dimitrova VI, Zotikov AE, Kalinina NI, Parfenova EV. The influence of high glucose concentration on the ability of mesenchymal stromal cells to stimulate blood vessel growth. Diabetes mellitus. 2011;(3):32-36.

Biscetti F, Pitocco D, Straface G, Zaccardi F, de Cristofaro R, Rizzo P, Lancellotti S, Arena V, Stigliano E, Musella T, Ghirlanda G, Flex A. Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clin Sci (Lond). 2011 Dec;121(12):555-564.

Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes. 2006 Aug;55(8):2245-2255.

Tanii M, Yonemitsu Y, Fujii T, Shikada Y, Kohno R, Onimaru M, Okano S, Inoue M, Hasegawa M, Onohara T, Maehara Y, Sueishi K. Diabetic microangiopathy in ischemic limb is a disease of disturbance of the plateletderived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res. 2006 Jan 6;98(1):55-62. Epub 2005 Nov 23.

Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002 Nov 26;106(22):2781-2786.

Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005 May 3;45(9):1449-1457.

Sibal L, Aldibbiat A, Agarwal SC, Mitchell G, Oates C, Razvi S, Weaver JU, Shaw JA, Home PD. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia. 2009 Aug;52(8):1464-1473. Epub 2009 May 30.

Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, Roguin A. Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res. 2010 Sep;126(3):166-174. Epub 2010 Mar 26.

Churdchomjan W, Kheolamai P, Manochantr S, Tapanadechopone P, Tantrawatpan C, U-Pratya Y, Issaragrisil S. Comparison of endothelial progenitor cell function in type 2 diabetes with good and poor glycemic control. BMC Endocr Disord. 2010 Apr 7;10:5.

Ruda MM, Arefieva TI, Sokolova AV, Shestakova MV, Karpov YuA, Parfenova EV. Circulating precursors of endothelial cells in patients with chd and disturbed carbohydrate metabolism. Diabetes mellitus. 2010;(1):13-20.

Kang L, Chen Q, Wang L, Gao L, Meng K, Chen J, Ferro A, Xu B. Decreased mobilization of endothelial progenitor cells contributes to impaired neovascularization in diabetes. Clin Exp Pharmacol Physiol. 2009 Oct;36(10):e47-56. Epub 2009 Jun 16.

Brunner S, Hoellerl F, Schmid-Kubista KE, Zeiler F, Schernthaner G, Binder S, Schernthaner GH. Circulating angiopoietic cells and diabetic retinopathy in type 2 diabetes mellitus, with or without macrovascular disease. Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4655-4662. Print 2011.

Fadini GP, Sartore S, Baesso I, Lenzi M, Agostini C, Tiengo A, Avogaro A. Endothelial progenitor cells and the diabetic paradox. Diabetes Care. 2006 Mar;29(3):714- 716.

Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler S, Zeiher A, Tiengo A, Avogaro A. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010 May;33(5):1097-1102. Epub 2010 Feb 11.

Loomans CJ, van Haperen R, Duijs JM, Verseyden C, de Crom R, Leenen PJ, Drexhage HA, de Boer HC, de Koning EJ, Rabelink TJ, Staal FJ, van Zonneveld AJ. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. Mol Med. 2009 May-Jun;15(5-6):152-159. Epub 2009 Mar 11.

Capla JM, Grogan RH, Callaghan MJ, Galiano RD, Tepper OM, Ceradini DJ, Gurtner GC. Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plast Reconstr Surg. 2007 Jan;119(1):59-70.

Shen C, Li Q, Zhang YC, Ma G, Feng Y, Zhu Q, Dai Q, Chen Z, Yao Y, Chen L, Jiang Y, Liu N. Advanced glycation endproducts increase EPC apoptosis and decrease nitric oxide release via MAPK pathways. Biomed Pharmacother. 2010 Jan;64(1):35-43. Epub 2009 Sep 3.

Chen Q, Dong L, Wang L, Kang L, Xu B. Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem Biophys Res Commun. 2009 Apr 3;381(2):192-197. Epub 2009 Feb 14.

Jung C, Rafnsson A, Shemyakin A, Böhm F, Pernow J. Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes. Int J Cardiol. 2010 Sep 3;143(3):368-372. Epub 2009 Apr 26.

Desouza CV, Hamel FG, Bidasee K, O'Connell K. Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction. Diabetes. 2011 Apr;60(4):1286-1294. Epub 2011 Feb 23.

Kahn MB, Yuldasheva NY, Cubbon RM, Smith J, Rashid ST, Viswambharan H, Imrie H, Abbas A, Rajwani A, Aziz A, Baliga V, Sukumar P, Gage M, Kearney MT, Wheatcroft SB. Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regeneration. Diabetes. 2011 Apr;60(4):1295-1303. Epub 2011 Feb 11.

van Oostrom O, de Kleijn DP, Fledderus JO, Pescatori M, Stubbs A, Tuinenburg A, Lim SK, Verhaar MC. Folic acid supplementation normalizes the endothelial progenitor cell transcriptome of patients with type 1 diabetes: a case-control pilot study. Cardiovasc Diabetol. 2009 Aug 25;8:47.

De Falco E, Avitabile D, Totta P, Straino S, Spallotta F, Cencioni C, Torella AR, Rizzi R, Porcelli D, Zacheo A, Di Vito L, Pompilio G, Napolitano M, Melillo G, Capogrossi MC, Pesce M. Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in diabetes mellitus. J Cell Mol Med. 2009 Sep;13(9B):3405-3414.

Fiorina P, Pietramaggiori G, Scherer SS, Jurewicz M, Mathews JC, Vergani A, Thomas G, Orsenigo E, Staudacher C, La Rosa S, Capella C, Carothers A, Zerwes HG, Luzi L, Abdi R, Orgill DP. The mobilization and effect of endogenous bone marrow progenitor cells in diabetic wound healing. Cell Transplant. 2010;19(11):1369-1381. Epub 2010 Aug 17.

Albiero M, Menegazzo L, Boscaro E, Agostini C, Avogaro A, Fadini GP. Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia. 2011 Apr;54(4):945-953. Epub 2010 Dec 17.

Liao YF, Chen LL, Zeng TS, Li YM, Fan Yu, Hu LJ, Ling Yue. Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med. 2010 Aug;15(4):279-285. Epub 2010 May 28.

Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am. Heart J. 2006; 152 (6): 1051.e1-e8.

Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor- 1alpha. Diabetes Care. 2010 Jul;33(7):1607-1609. Epub 2010 Mar 31.

Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, Gröger M, Fialka-Moser V, Gschwandtner M, Koppensteiner R, Steiner S. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial. Atherosclerosis. 2011 Jul;217(1):240- 248. Epub 2011 Apr 8.

Jaumdally RJ, Goon PK, Varma C, Blann AD, Lip GY. Effects of atorvastatin on circulating CD34+/CD133+/CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med. 2010 Apr;267(4):385-393. Epub 2009 Jul 16.

Reinhard H, Jacobsen PK, Lajer M, Pedersen N, Billestrup N, Mandrup-Poulsen T, Parving HH, Rossing P. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia. 2010 Oct;53(10):2129-2133. Epub 2010 Jul 6.

Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012 Jan;87(1):77-88.

Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double- masked, multicenter phase II study. Diabetes Care. 2010 Nov;33(11):2399-2405.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):615- 625.

Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA; READ-2 Study Group. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009 Nov;116(11):2175-2181.e1. Epub 2009 Aug 22.

Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010 Nov;117(11):2146-2151. Epub 2010 Sep 19.

Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Rückert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS. The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology. 2011 Sep;118(9):1819-1826. doi: 10.1016/j.ophtha. 2011.02.018. Epub 2011 May 5.

Kimoto K, Kubota T. Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol. 2012;2012:852183. Epub 2011 Nov 3.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006 Oct;113(10):1695.e1-15.

Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U. Repeated intravitreal bevacizumab (AvastinÂ) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011 Feb;89(1):76-81. doi: 10.1111/j.1755-3768.2009.01622.x.

Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010 Sep;94(9):1215-1218. Epub 2010 Jun 10.

Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2011 May 11;(5):CD008214.

100

Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H. Peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes. 2004 Jul;53(7):1831-1840.

101

Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 2006 Feb;17(2):475-486. Epub 2006 Jan 4.

102

Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, Sonoda H, Sato Y, Makino H. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes. 2009 Oct;58(10):2365- 2375. Epub 2009 Jul 8.

103

Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol. 2006 Nov;17(11):3093-3104. Epub 2006 Sep 20.

104

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008 Mar 13;358(11):1129- 1136.

105

Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010 Jan;46(2):439-448. Epub 2009 Dec 16.

106

Van Slyke P, Alami J, Martin D, Kuliszewski M, Leong-Poi H, Sefton MV, Dumont D. Acceleration of diabetic wound healing by an angiopoietin peptide mimetic. Tissue Eng Part A. 2009 Jun;15(6):1269-1280.

107

Amin AH, Abd Elmageed ZY, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, Matrougui K. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010 Jul;90(7):985-996. Epub 2010 May 3.

108

Barcelos LS, Duplaa C, Kränkel N, Graiani G, Invernici G, Katare R, Siragusa M, Meloni M, Campesi I, Monica M, Simm A, Campagnolo P, Mangialardi G, Stevanato L, Alessandri G, Emanueli C, Madeddu P. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res. 2009 May 8;104(9):1095-1102. Epub 2009 Apr 2.

109

Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009 Oct 9;105(8):724- 736.

110

Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008347.

111

De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez- Aguilar E, Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels. 2009 Sep;24(5):321-328. Epub 2009 Sep 27.

112

Kawamura A, Horie T, Tsuda I, Abe Y, Yamada M, Egawa H, Iida J, Sakata H, Onodera K, Tamaki T, Furui H, Kukita K, Meguro J, Yonekawa M, Tanaka S. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs. 2006;9(4):226-233. Epub 2006 Dec 21.

113

Ruiz-Salmeron R, de la Cuesta-Diaz A, Constantino-Bermejo M, Pérez-Camacho I, Marcos-Sánchez F, Hmadcha A, Soria B. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplant. 2011;20(10):1629-1639.

The authors declare that there are no conflicts of interest present.